An open label, dose escalataion study investigating pharmacokinetics, safety and tolerability of liposomal Amphotericin B in immunocompromised children and adolescents

Trial Profile

An open label, dose escalataion study investigating pharmacokinetics, safety and tolerability of liposomal Amphotericin B in immunocompromised children and adolescents

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Amphotericin B liposomal (Primary)
  • Indications Aspergillosis; Mycoses; Visceral leishmaniasis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Dec 2016 New trial record
    • 14 Nov 2016 Results published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top